Zoetis Inc. (ZTS)
NYSE · Parsippany, New Jersey, USA · Founded 1952 · CEO Kristin Peck
Valuation summary
$77.77 fair value versus $80.79 in the market, a difference of -3.7%. Rated Hold.
| Fair value per share | $77.77 |
| Current share price | $80.79 |
| Upside / downside | -3.7% |
| Bear case | $47.72 |
| Bull case | $121.32 |
| Discount rate (WACC) | 8.4% |
| Terminal growth | 2.80% |
| Market capitalisation | $33B |
| EV / Sales | 4.3x |
About Zoetis Inc.
Spun out of Pfizer in 2013, with roots in Pfizer's animal health division dating to 1952. Kristin Peck has been CEO since 2020. Zoetis is the largest animal health company in the world, making vaccines, parasiticides and medicines for both pets and livestock. The companion animal business is the attractive part: pet owners increasingly treat animals as family members and spend accordingly, and veterinary medicines face no insurance reimbursement pressure.
Investment case
- Pet humanisation is a durable spending trend largely insulated from economic cycles.
- No payer or reimbursement pressure, unlike human pharmaceuticals — owners pay directly.
- Librela and Solensia, monoclonal antibodies for osteoarthritis pain, opened a genuinely new category.
Key risks
- US companion animal sales fell 11% in the second quarter of 2026 on softer demand, price sensitivity, competition and generic pressure on Cerenia and Convenia, prompting a second guidance cut in August 2026.
- Livestock demand is tied to protein prices and farm economics.
- Lower US Librela sales, following reports of adverse events, show prescriber caution is now affecting revenue.
Recent developments
- 2026-08-06 · Q2 2026 revenue $2.468bn, flat (down 1% organic); US companion animal down 11%; 2026 revenue guidance cut to $9.12-$9.32bn and adjusted EPS to $6.15-$6.25 source
Revenue by segment
| Companion Animal | 65% |
| Livestock | 34% |
| Other | 1% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $9.5B | $2.4B |
| Year 2 | $9.7B | $2.4B |
| Year 3 | $9.9B | $2.4B |
| Year 4 | $10.0B | $2.4B |
| Year 5 | $10.2B | $2.3B |
What the street says
Once considered a high-quality, defensive compounder, Zoetis is now viewed as a business facing a more pressured US companion animal market. In August 2026 it cut 2026 guidance to revenue of $9.12-$9.32bn and adjusted EPS of $6.15-$6.25, from $9.68-$9.96bn and $6.85-$7.00, and the debate is whether the US slowdown is cyclical or competitive.
Comparable companies: BIIB · GSK · PFE · TEVA · BDX · DHR · NVO · TAK
Open the interactive model, price chart and sensitivity grid →